We show that NGS of DNA from schedule FFPE endoscopic biopsy or EMR samples can be employed to detect genomic mutations in nonneoplastic BIM with significant analytical sensitivity. The opportunity to detect mutations in nonneoplastic mucosa, quantitatively and with higher detection sensitivity, causes it to be achievable to implement NGS http://popec184cxq4.blogofchange.com/profile